Lung Cancer

Expert perspectives on identifying, monitoring, and managing treatment-related toxicities in lung cancer.

Lung Cancer

Group photo of three medical professionals discussing BRAF and MEK inhibitor side effects in NSCLC, featuring Dr. Melissa Johnson, Dr. Rohit Gosain, and Dr. Rahul Gosain.

Lung Cancer

05/28/2026

BRAF and MEK Inhibitor Side Effects in BRAF V600E–Mutated NSCLC

Melissa Johnson, MDRahul Gosain, MD, MBARohit Gosain, MD

Expert discussion on managing side effects of EGFR inhibitors in non-small cell lung cancer (NSCLC) with Dr. Azam Farooqi, Dr. Joshua Sabari, Dr. Rohit Gosain, and Dr. Rahul Gosain.

Lung Cancer

05/18/2026

How To Manage Side Effects of EGFR Inhibitors in NSCLC

Azam Farooqui, MDJoshua Sabari, MDRahul Gosain, MD, MBARohit Gosain, MD

Toxicity awareness in novel antibody-drug conjugates and NSCLC, featuring expert insights from Dr. Jacob Sands, Dr. Rohit Gosain, and Dr. Rahul Gosain on key adverse effects and safety considerations.

Lung Cancer

01/02/2026

Key Adverse Effects of Novel Antibody-Drug Conjugates in NSCLC

Jacob Sands, MDRahul Gosain, MD, MBARohit Gosain, MD

Optimizing ROS1 inhibitor therapy in NSCLC with insights from Dr. Estelamari Rodriguez and colleagues for cancer research and targeted lung cancer treatment.

Lung Cancer

11/15/2025

Optimizing ROS1 Inhibitor Therapy in NSCLC

Estelamari Rodriguez, MD, MPHRohit Gosain, MDRahul Gosain, MD, MBA

Expert panel discussing management of anti-EGFR toxicities in NSCLC treatment strategies.

Lung Cancer

05/28/2025

How to Manage Anti-EGFR Toxicities in NSCLC

Gilberto Lopes, MD